Julia Qian
About Julia Qian
Julia (LinLin) Qian, 50, is Chief Financial Officer (since September 2022) and a member of the Board of Directors (since April 2024) at Health In Tech (HIT). She brings 20+ years across global financial services and capital markets, including leadership roles at Citi and The Blueshirt Group, with a Bachelor in International Accounting (Shanghai University of Finance and Economics, 1995) and an MBA (Shanghai Jiaotong University, 2003) . Under her finance leadership, HIT delivered Q3 2025 revenue of $8.5 million (+90% YoY), nine‑month revenue of $25.8 million, and Q3 2025 adjusted EBITDA of $1.0 million (+49% YoY) . She is not an independent director per Board determination .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Citi Group (incl. Citi FinTech) | Senior VP, US retail banking & distribution; Strategy Lead, Global Consumer Bank; Regional Director, Secured Lending Asia | 2012–2018 | Led strategy and operating roles in consumer banking, distribution, and secured lending across the U.S. and Asia . |
| The Blueshirt Group | Managing Director | 2018–2022 | Capital markets and investor relations leadership supporting public company communications and market engagement . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Health In Tech (Board of Directors) | Director | Apr 2024–present | Finance and capital markets expertise added to Board; not independent under Nasdaq rules . |
Fixed Compensation
| Metric | 2023 | 2024 |
|---|---|---|
| Base Salary ($) | 360,000 | 360,000 |
| Cash Bonus ($) | 86,000 | 47,500 |
Performance Compensation
| Equity Award (Type) | Grant Date | Shares/Value | Key Terms | Vesting |
|---|---|---|---|---|
| Restricted Stock Awards (RSAs) – Program 1 & Program 2 | Aug 15, 2025 | 10,000 (Program 1) and 17,000 (Program 2) shares | Tied to launching two programs successfully and being fully operational | 50% vests in equal monthly installments over 12 months from the first program’s launch; remaining 50% vests monthly over 12 months from the second program’s launch . |
| Restricted Stock Award – “Initiative” | Sep 24, 2025 | 80,000 shares | Milestone‑based vesting tied to (1) LOI/MOU sign, (2) proof‑of‑concept/beta launch, (3) full commercial launch | Each one‑third tranche vests in equal monthly installments over 12 months beginning at each milestone start date . |
| Stock Awards (Grant‑date fair value) | 2023 | $107,806 | 2022 Plan equity awards; service‑based vesting post‑IPO | As specified by award agreements . |
| Option Awards (Grant‑date fair value) | 2023 | $502,800 | 2022 Plan options; service‑based vesting post‑IPO | As specified by option agreements . |
Outstanding Equity Awards (as of Dec 31, 2024)
| Instrument | Grant Date | Exercisable | Unexercisable | Exercise Price ($) | Expiration | Unvested Stock (Shares) | Market Value ($) |
|---|---|---|---|---|---|---|---|
| Stock Options | 07/01/2023 | 103,100 | 608,410 | 0.71 | 07/01/2028 | — | — |
| Restricted Stock | 07/01/2023 | — | — | — | — | 120,090 | 84,864 |
Equity Ownership & Alignment
| Ownership Metric | Value |
|---|---|
| Class A Common Shares | 8,689,185 (18.69% of Class A) |
| Class B Common Shares | 2,700,000 (23.08% of Class B; 10 votes per share; convertible 1:1 into Class A) |
| Total Voting Power | 21.83% |
| Included in beneficial ownership | 55,193 restricted shares; 640,630 underlying stock options |
| Excluded from beneficial ownership (near‑term vesting) | 70,880 options vest after 60 days from Sep 8, 2025 |
- Hedging/pledging: Insider policy prohibits margining company securities as collateral; prohibits short sales and derivatives; 10b5‑1 trading plans permitted under defined parameters .
- Equity plan supply: 2024 Plan amendments increased Class A share reserve to 10,677,849 and added up to 2,000,000 Class B shares for executive officers; approved by shareholders on Oct 3, 2025 .
Employment Terms
- Employment Agreement: At‑will; base salary $360,000; discretionary annual cash bonus; eligible for equity awards; benefits (health, life, disability) and reimbursement of reasonable expenses .
- Restrictive Covenants: Invention assignment, confidentiality; non‑compete and non‑solicit during employment and for two years thereafter .
- Clawback: Board‑adopted policy to recoup excess incentive compensation following a financial restatement (Section 10D/Nasdaq); amount equals incentive paid over what would have been paid on restated results; reasonable estimate permitted when direct calculation is not feasible .
- Change‑in‑Control (Equity): Compensation Committee may cancel for cash, assume/substitute awards, accelerate vesting, purchase awards for cash, or otherwise adjust on change‑in‑control .
- Indemnification: Executive indemnification agreements and Nevada corporate indemnification to fullest extent permitted .
Board Governance and Director Service
- Board role: Director since April 2024 ; not independent (Nasdaq) along with CEO Tim Johnson .
- Committees: Audit (Hayes—Chair), Compensation (Umemezia—Chair), Nominating & Governance (Howard—Chair). Committee memberships listed comprise independent non‑employee directors; Qian is not listed on these committees .
- Board meetings: No Board meetings held in 2024 due to IPO timing (Dec 24, 2024) .
- Director compensation (non‑employee directors): Annual $120,000 ($40,000 cash + $80,000 restricted stock, 1‑year vest); committee chair fees—Audit $20,000; Compensation $10,000; Nominating $10,000; equity granted at annual meeting, prorated for new directors .
Performance & Track Record (HIT Operating Results Under CFO)
| Metric | Q3 2024 | Q3 2025 |
|---|---|---|
| Total Revenues ($) | 4,458,921 | 8,490,093 |
| Adjusted EBITDA ($) | 668,863 | 999,056 |
| Income Before Tax ($) | 406,739 | 600,222 |
- Nine‑month 2025: Revenues $25.8M; Adjusted EBITDA $3.8M; Pre‑tax income $2.1M; cash $8.0M .
Compensation Structure Analysis
- Increased equity linkage and milestone‑based RSAs in 2025 tie vesting to program launches and commercialization milestones, improving pay‑for‑performance alignment versus pure time‑based vesting .
- Option overhang and near‑term vesting: 70,880 options excluded from beneficial ownership because they vest after 60 days from Sep 8, 2025, which can create incremental supply upon vesting .
- Share pool expansion and dual‑class awards (Class B for executives) increase potential dilution and voting concentration among executive officers .
Risk Indicators & Red Flags
- Governance concentration: Dual role as CFO and Director with non‑independent status; Board committees are independent, but concentration of voting power via Class B shares (10 votes per share; convertible) raises control risk .
- Dilution risk: 2024 Plan amendments add 3,000,000 Class A and 2,000,000 Class B shares available for awards, approved Oct 3, 2025 .
- Trading policy mitigants: Explicit prohibitions on hedging and pledging via margin reduce misalignment risk; Rule 10b5‑1 permitted for orderly trading .
Investment Implications
- Alignment: Large personal stake (21.83% voting power) and milestone‑based RSAs align incentives with program execution and commercialization, supportive of near‑term growth and quality of earnings .
- Overhang: Multiple tranches of RSAs and options (including near‑term vesting options) may introduce selling pressure as awards vest; watch for 10b5‑1 filings and vesting cadence .
- Control and dilution: Expansion of equity plan and executive‑only Class B issuance increases potential future dilution and concentrates governance; monitor additional awards and any conversions of Class B into Class A .
- Execution: Strong YoY revenue and EBITDA growth in 2025 improve confidence in operating momentum under Qian’s finance leadership; continued scalability depends on successful program launches tied to RSAs .